Valuation: Sopharma AD

Market Cap 3.28B 1.97B 1.77B 1.63B 1.48B 2.76B 187B 2.8B 19.52B 7.78B 98.1B 7.39B 7.23B 311B P/E 2024
12.3x
P/E 2025 7.16x
Enterprise Value 3.82B 2.29B 2.06B 1.9B 1.72B 3.22B 218B 3.26B 22.75B 9.06B 114B 8.61B 8.42B 363B EV / Sales 2024
0.66x
EV / Sales 2025 0.76x
Free-Float
31.06%
Yield 2024
2.68%
Yield 2025 5.02%
1 day-0.61%
1 week+7.57%
Current month+26.25%
1 month+26.74%
3 months+72.11%
6 months+89.02%
Current year+129.54%
1 week 3.08
Extreme 3.08
3.37
1 month 2.49
Extreme 2.49
3.37
Current year 1.41
Extreme 1.41
3.37
1 year 1.34
Extreme 1.339518
3.37
3 years 0.94
Extreme 0.940394
3.37
5 years 0.68
Extreme 0.681551
3.37
10 years 0.41
Extreme 0.408688
3.37
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2000
Director of Finance/CFO - 01/01/2002
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 42 19/05/2010
Director/Board Member 63 19/05/2010
Director/Board Member 61 12/07/2011
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/20
Donev Investments Ad
BuyCompany 25,489 0.0189%
30/9/20 Buy

Chief Executive Officer

12,000 0.0089%
29/9/20
Donev Investments Ad
BuyCompany 9,000 0.0067%
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%+7.57%+136.84%+167.18% 1.96B
-1.83%-8.44%-42.11%+1.93% 15.09B
-3.51%-2.95%-12.69%-3.00% 6.5B
-3.20%-4.87%-19.24%+0.07% 6.38B
0.00%-8.52%-53.88%-39.87% 5.75B
-14.44%-25.66%-17.58%-36.80% 5.28B
-2.58%-3.37%-1.70%-10.64% 4.65B
-0.16%+1.10%+0.27%-22.87% 3.16B
-4.58%-7.95%-17.72%-20.57% 3.17B
+0.91%-8.76%-38.49%-14.96% 3.14B
Average -3.00%-4.79%-6.63%+2.05% 5.51B
Weighted average by Cap. -3.13%-5.86%-21.04%-5.80%

Financials

2024 2025
Net sales 2.14B 1.28B 1.15B 1.07B 965M 1.8B 122B 1.83B 12.74B 5.08B 64.04B 4.82B 4.72B 203B 2.63B 1.58B 1.42B 1.31B 1.19B 2.22B 151B 2.25B 15.68B 6.25B 78.8B 5.93B 5.81B 250B
Net income 77.85M 46.75M 41.95M 38.78M 35.12M 65.62M 4.45B 66.41M 464M 185M 2.33B 175M 172M 7.4B 134M 80.19M 71.95M 66.52M 60.25M 113M 7.64B 114M 795M 317M 4B 301M 295M 12.69B
Net Debt 444M 267M 239M 221M 200M 374M 25.41B 379M 2.65B 1.05B 13.3B 1B 980M 42.21B 541M 325M 292M 270M 244M 456M 30.96B 462M 3.22B 1.28B 16.2B 1.22B 1.19B 51.43B
Projected Income Statement - Annual - Sopharma AD
Logo Sopharma AD
Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.
Employees
6,049
Date Price Change Volume
28/10/26 €3.280 +0.31% 39,789
27/10/26 €3.270 -0.61% 56,773
26/10/26 €3.290 -0.90% 30,115
23/10/26 €3.320 +3.75% 41,241
22/10/26 €3.200 +3.90% 40,227

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Sopharma AD